A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors

• Status: Completed
• Trial end date: 2020-12-18
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine safety and effectiveness of experimental medication BMS-986205 in combination with Nivolumab in patients with cancers that are advanced or have spread.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Linrodostat; Nivolumab

Criteria

Inclusion Criteria:

• Participants must have histologic or cytological confirmation of a solid tumor that is advanced with measureable disease per RECIST v1.1

• Participants must have received, and then progressed or been intolerant to at least one standard treatment regimen in the advanced or metastatic setting

• Participants must have an ECOG performance status of less than or equal to 1

• Participants must have at least 1 lesion with measurable disease as defined by RECIST Version 1.1

Exclusion Criteria:

• Participants must not have suspected, known, or progressive CNS metastases, have untreated CNS metastases, or have the CNS as the only site of disease

• Participants with prior exposure to anti PD-1 or anti-PDL1 therapy

• Participants must not have a history of allergy to any of the study treatment components